With 1 ETF traded in the U.S. markets, MVIS US Listed Biotech 25 Index ETF gathers total assets under management of $487.49M. The average expense ratio is 0.35%. MVIS US Listed Biotech 25 Index ETF can be found in the following asset class:
- Equity
With 1 ETF traded in the U.S. markets, MVIS US Listed Biotech 25 Index ETF gathers total assets under management of $487.49M. The average expense ratio is 0.35%. MVIS US Listed Biotech 25 Index ETF can be found in the following asset class:
See the top-performing biotech ETFs and the potential benefits of investing.
It's easy to be blinded by headline numbers. The rally in biotech isn't so simple.
ETFs are becoming core holdings for institutions.
High-flying ETFs in several sectors eclipsed the S&P 500 gains.
Multiple factors are setting the sector up for further growth in 2014.
The latest tally of year-to-date top-10-performing ETFs include Japan, clean energy and biotech funds, to name a few.
Who knew Egypt would be the best ETF as the third quarter draws to a close?